ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
CSL LIMITED
174.260
+2.690
1.57%
成交量:
141.14萬
成交額:
2.45億
市值:
834.55億
市盈率:
-23.22
高:
174.300
開:
172.800
低:
171.290
收:
171.570
52周最高:
216.741
52周最低:
88.833
股本:
4.79億
流通股本:
4.79億
量比:
1.36
換手率:
0.29%
股息:
4.10
股息率:
2.35%
每股收益(TTM):
-7.505
每股收益(LYR):
-7.505
淨資產收益率:
-15.83%
總資產收益率:
7.26%
市淨率:
4.02
市盈率(LYR):
-23.22
資料載入中...
總覽
公司
新聞資訊
公告
概念
新冠治療股
+0.93%
醫藥生物股
+1.18%
ESG概念
-1.14%
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
英國監管機構因數據不可靠,暫停安進公司Tavneos用於新患者
路透中文
·
09/01
CSL重大擴產計劃:大幅提升免疫球蛋白及白蛋白生產能力,惠及罕見病與重症患者
美股速递
·
09/01
CSL達成協議:為美國藥品定價及特定232條款關税風險增添確定性
美股速递
·
09/01
CSL有限公司:項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位
美股速递
·
09/01
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/CSL.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":174.26,"timestamp":1789452720000,"preClose":171.57,"halted":0,"volume":1411389,"delay":0,"changeRate":0.015678731713003425,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.50665426314822,"marketStatus":"未開盤","change":2.69,"latestTime":"09-15 16:12:00 AEST","open":172.8,"high":174.3,"low":171.29,"amount":244800924,"amplitude":0.017544,"askPrice":174.3,"askSize":250,"bidPrice":174,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-7.50665426314822,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":171.57,"dividendRate":0.023383,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":1.359264,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":171.57,"auctionPrice":174.26,"auctionVolume":482851,"auction":3,"marketStatus":"盘后竞价","timestamp":1789452615853}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.505243,"volumeRatio":1.359264,"shares":478911979,"dividePrice":4.09632,"high":174.3,"amplitude":0.017544,"preClose":171.57,"low":171.29,"week52Low":88.833,"pbRate":"4.02","psRate":"3.77","week52High":216.741,"institutionHeld":0,"latestPrice":174.26,"committee":-0.612903,"eps":-7.505243148835284,"divideRate":0.023507,"volume":1411389,"delay":0,"ttmEps":-7.505243148835284,"open":172.8,"prevYearClose":168.21,"prevWeekClose":167.1,"prevMonthClose":169.351,"prevQuarterClose":113.256,"fiveDayClose":172.539,"twentyDayClose":155.779,"sixtyDayClose":110.591,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664347855","title":"英國監管機構因數據不可靠,暫停安進公司Tavneos用於新患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664347855","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664347855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"英国监管机构因数据不可靠,暂停安进公司Tavneos用于新患者路透9月1日-英国药品监管机构周二暂停了安进公司旗下AMGN.O研发的罕见病药物Tavneos对新患者的使用和销售,称支持该药获批的主要研究结果不可靠。监管机构表示,由于主要临床试验的数据不可靠,该研究已无法证明该药有效,也无法证明其益处大于风险。Tavneos由ChemoCentryx公司研发,安进公司于2022年以37亿美元收购了该公司。欧洲委员会于8月撤销了Tavneos的批准,此前监管机构发现其关键试验数据不可靠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","LU0058720904.USD","LU0889565916.HKD","LU2242646821.SGD","IE0002141913.USD","LU0868494617.USD","BK4581","LU1571399168.USD","LU2089984988.USD","BK7508","IBBQ","LU2112291526.USD","BK4139","IE00BJT1NW94.SGD","LU1023059063.AUD","IBB","LU1983299246.USD","LU0289739699.SGD","LU0122379950.USD","TBXU","SG9999001440.SGD","BK4588","LU1061106388.HKD","CSL.AU","IE00B2B36J28.USD","PBE","BK4533","IE00BJJMRZ35.SGD","BK7067","LU2242652126.USD","LU2468319806.SGD","BK7511","AMGN","BIB","IE00BFTCPJ56.SGD","PJP","LU1057294990.SGD","BBH","LU0320765992.SGD","BK7501","LU0109394709.USD","BK4534","BK4585","BK4566","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160995524","title":"CSL重大擴產計劃:大幅提升免疫球蛋白及白蛋白生產能力,惠及罕見病與重症患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1160995524","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160995524?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:27","pubTimestamp":1788204431,"startTime":"0","endTime":"0","summary":"CSL宣布了一项重大扩建项目,此举将显著增强其为罕见疾病及严重病症患者生产免疫球蛋白和白蛋白的能力。这一战略性举措不仅标志着公司在生物制药领域迈出的坚实一步,更意味着全球更多患者有望获得这些关键性治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181327820","title":"CSL達成協議:為美國藥品定價及特定232條款關税風險增添確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1181327820","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181327820?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:25","pubTimestamp":1788204309,"startTime":"0","endTime":"0","summary":"CSL宣布,已通过相关协议为其在美国药品定价及部分第232条款关税方面的潜在风险敞口提供了更多确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194972911","title":"CSL有限公司:項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位","url":"https://stock-news.laohu8.com/highlight/detail?id=1194972911","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194972911?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:24","pubTimestamp":1788204248,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布,其新项目将带来显著的就业增长。据估计,该项目将直接催生至少300个制药制造领域的全新工作岗位。与此同时,建筑业及相关配套行业也将迎来约800个就业机会。这一系列的岗位创造计划,无疑将为当地经济注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CSL.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"新冠治療股","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":0.00931},{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.011805},{"market":"AU","name":"ESG概念","id":"package_au_concept_esggn","bkCode":"BK7511","changeRate":-0.011381}]}}